PE/Cyanine7 anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_PECy7_020608
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE/Cyanine7 (filled histogram) or Armenian hamster IgG PE/Cyanine7 isotype control (open histogram).
  • 145-2C11_PECy7_020608
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE/Cyanine7 (filled histogram) or Armenian hamster IgG PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100319 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100320 100 µg 159€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Aguilar EG, et al. 2021. Blood Adv. 5:4219. PubMed
  2. Meng J, et al. 2022. Cell Rep. 38:110492. PubMed
  3. Ocaña-Guzman R, et al. 2022. Cells. 11: . PubMed
  4. Zhang Y, et al. 2022. Vaccines (Basel). 10: . PubMed
  5. Dölz M, et al. 2022. iScience. 25:105372. PubMed
  6. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  7. Huang Y, et al. 2015. Proc Natl Acad Sci U S A. 112:39. PubMed
  8. Cabañero D, et al. 2020. Elife. 9:00. PubMed
  9. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  10. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  11. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  12. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  13. Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed
  14. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  15. Wang Z, et al. 2023. J Cancer. 14:1049. PubMed
  16. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  17. Oetjen LK et al. 2017. Cell. 171(1):217-228 . PubMed
  18. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  19. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  20. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  21. Li ZX, et al. 2022. Arch Virol. :. PubMed
  22. Zhu H, et al. 2018. Elife. 7:. PubMed
  23. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  24. Gopinathan G, et al. 2022. Mol Cancer Ther. 21:1030. PubMed
  25. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  26. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  27. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  28. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  29. Schulthess J et al. 2019. Immunity. 50(2):432-445 . PubMed
  30. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  31. Li Z, et al. 2022. Elife. 11:. PubMed
  32. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  33. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  34. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  35. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  36. Tuttle KD, et al. 2020. Cell Rep. 33:108407. PubMed
  37. Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed
  38. Emgård J, et al. 2018. Immunity. 143:419. PubMed
  39. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  40. Westfall S, et al. 2020. Brain Behav Immun. . PubMed
  41. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
  42. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  43. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  44. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  45. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
  46. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  47. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  48. Lu M, et al. 2021. J Virol. 95:e0059221. PubMed
  49. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  50. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  51. Tran NT, et al. 2020. STAR Protocols. 1(1):100028. PubMed
  52. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  53. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  54. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  55. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  56. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  57. Williams JW, et al. 2017. Circ Res. 121:662. PubMed
  58. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  59. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  60. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  61. Li J, et al. 2013. Arch Immunol Ther Exp (Warsz). 61:237. PubMed
  62. Huang Y, et al. 2016. J Immunol. 196: 217 - 231. PubMed
  63. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  64. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  65. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  66. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  67. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  68. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  69. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  70. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  71. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  72. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  73. Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed
  74. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  75. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  76. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  77. Hong JP, et al. 2020. Cell Reports Medicine. 1(3):100035. PubMed
  78. Qi Q, et al. 2009. Blood. 114:564. PubMed
  79. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
  80. Fite BZ, et al. 2021. Sci Rep. 11:927. PubMed
  81. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  82. Walker JA, et al. 2020. Immunity. 51(1):104-118. PubMed
  83. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  84. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  85. Wang Y, et al. 2020. Immunity. 53(6):1168-1181.e7. PubMed
  86. Goc J, et al. 2021. Cell. 184:5015. PubMed
  87. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  88. Ioanna E Galani et al. 2017. Immunity. 46(5):875-890 . PubMed
  89. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  90. Uematsu T, et al. 2015. Sci Rep. 5: 17577. PubMed
RRID
AB_312684 (BioLegend Cat. No. 100319)
AB_312685 (BioLegend Cat. No. 100320)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11-30-2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account